- Conditions
- ALS, Amyotrophic Lateral Sclerosis
- Interventions
- Fosigotifator, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Irvine, California • Los Angeles, California • San Francisco, California + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 4,097
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurological Disorder, Autoimmune Diseases
- Interventions
- Mycophenolate Mofetil, Azathioprine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Miami, Florida • Chicago, Illinois + 12 more
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- Methylphenidate Hydrochloride Extended Release Capsules, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Irvine, California • National City, California + 13 more
- Conditions
- Mild Cognitive Impairment (MCI), Sarcopenia
- Interventions
- Tai Chi
- Behavioral
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Athens, Ohio
- Conditions
- Arthritis, Osteoarthritis
- Interventions
- tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
- Biological · Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 832 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 94
- States / cities
- Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 72 more
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury
- Interventions
- Magnetic Levator Prosthesis (MLP)
- Device
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pain, Chronic Pain, Neuropathic Pain
- Interventions
- Evoke
- Device
- Lead sponsor
- Saint Francis Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Peripheral nerve ultrasound, Measurement of strength
- Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
- Interventions
- Liraglutide 6 mg Solution for Injection, Placebo
- Drug · Other
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- NF type1 With Inoperable Plexiform Neurofibromas
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 2 Years to 130 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Sciatica
- Interventions
- Oral Prednisone
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Santa Rosa, California
- Conditions
- Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2031
- U.S. locations
- 3
- States / cities
- Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
- Conditions
- Closed Femur Fracture
- Interventions
- Blood Flow Restriction, Delfi PTSII Tourniquet System
- Other · Device
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Bethesda, Maryland + 5 more
- Conditions
- Dermatomyositis
- Interventions
- Tofacitinib
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- WVE-210201, Placebo
- Drug
- Lead sponsor
- Wave Life Sciences USA, Inc.
- Industry
- Eligibility
- 5 Years to 18 Years · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 14
- States / cities
- Loma Linda, California • Los Angeles, California • Gainesville, Florida + 10 more
- Conditions
- Sarcopenia
- Interventions
- Culinary Medicine, Control
- Behavioral
- Lead sponsor
- Texas Tech University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
- Other · Device · Dietary Supplement + 1 more
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Myasthenia Gravis
- Interventions
- eculizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
- Conditions
- Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2026
- U.S. locations
- 16
- States / cities
- San Diego, California • Stanford, California • Aurora, Colorado + 12 more
- Conditions
- Type 2 Spinal Muscular Atrophy
- Interventions
- OAV101, Sham control
- Genetic · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Farmington, Connecticut • Chicago, Illinois • Strasburg, Pennsylvania + 2 more
- Conditions
- Chronic Fatigue Syndrome
- Interventions
- Not listed
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Stony Brook, New York